Amarin Corp Plcuk (AMRN) - News Archive

Amarin s Breakthrough with VAZKEPA Reimbursement in Italy Amidst Market Challenges Amarin Corporation, recognized globally for its novel pharmaceutical advancements, has received a national reimbursement approval in Ita...

Subgroup Data and Mechanistic Insights of VASCEPA/VAZKEPA (Icosapent Ethyl) to Be Showcased at Major Cardiological Conferences in 2024Dublin, Ireland, and Bridgewater, N.J. August 22, 2024 Amarin Corporation plc (NASDAQ...

Amarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in PortugalThe Portuguese Ministry of Health has recently granted national reimbursement approval for VAZKEPA (icosapent ethyl), a medication designed...

Amarin s Flagship Medication VASCEPA Receives Regulatory Approval in Mainland China, Paving the Way for Cardiovascular Risk ReductionIn a groundbreaking development, Amarin s strategic partner, EddingPharm, has received...

Amarin s VAZKEPA Receives National Reimbursement in Greece, Expands European Market Presence with Exclusive Agreement with Vianex S.A.In a substantial development for Amarin Corporation, the Greek Ministry of Health has...

In recent months, Amarin Corporation has been at the forefront of advocating for patient safety and pushing for regulatory action against the prescribing of fenofibrate in patients at risk of cardiovascular events. Supp...

Amarin Shareholders Approve $50 Million Share Repurchase ProgramAmarin Corp Plcuk held its Annual General Meeting of Shareholders where shareholders approved a share repurchase program of up to $50 million. This decisio...

Revealing Mechanistic Insights into EPA Sheds Light on VASCEPA/VAZKEPA s Potential Mechanism of ActionAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 Data Further Adv...

The groundbreaking REDUCE-IT trial has demonstrated the remarkable cardioprotective effects of VASCEPA/VAZKEPA (Icosapent Ethyl) in reducing cardiovascular events in high-risk patients. Recently published articles by le...

The American College of Cardiology s (ACC) Annual Scientific Session & Expo, scheduled for April 6-8, 2024, will showcase new research on the benefits of VASCEPA/VAZKEPA (icosapent ethyl) and reveal mechanistic data on...

In a recent press release, Amarin Corporation plc (NASDAQ:AMRN) shared a letter addressed to its shareholders. The letter, authored by Chairman of the Board Odysseas Kostas, M.D. and President & CEO Patrick Holt, provid...